(Q42687809)

4 November 2017

title

Immunomodulatory treatment of multiple sclerosis in denmark: a prospective nationwide survey (English)

1 reference

4 November 2017

0 references

0 references

Per Soelbeg Sorensen

1

1 reference

4 November 2017

Nils Koch-Henriksen

2

1 reference

4 November 2017

Mads Ravnborg

3

1 reference

4 November 2017

Jette Lautrup Frederiksen

4

1 reference

4 November 2017

Kai Jensen

5

1 reference

4 November 2017

Anne Heltberg

6

1 reference

4 November 2017

Hanne Schaldemose

7

1 reference

4 November 2017

Sven Deth

8

1 reference

4 November 2017

Ole Kristensen

9

1 reference

4 November 2017

Mogens Worm

10

1 reference

4 November 2017

Egon Stenager

11

1 reference

4 November 2017

Hans Jacob Hansen

12

1 reference

4 November 2017

Bjarne Sivertsen

13

1 reference

4 November 2017

Jesper Torring

14

1 reference

4 November 2017

Danish Multiple Sclerosis Study Group

15

1 reference

4 November 2017

publication date

1 June 2006

1 reference

Multiple Sclerosis Journal

4 November 2017

published in

1 reference

4 November 2017

volume

12

1 reference

4 November 2017

issue

3

1 reference

4 November 2017

page(s)

253-264

1 reference

The Danish National Project of interferon-beta treatment in relapsing-remitting multiple sclerosis. The Danish Multiple Sclerosis Group.

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1323OA

A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1323OA

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1323OA

Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1323OA

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1323OA

Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1323OA

Long-term interferon-beta treatment for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1323OA

Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1323OA

A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1323OA

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1323OA

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1323OA

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1323OA

A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1323OA

Comparison of glatiramer acetate (Copaxone) and interferon beta-1b (Betaferon) in multiple sclerosis patients: an open-label 2-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1323OA

A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1323OA

Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1323OA

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F135248506MS1323OA

10.1191/135248506MS1323OA

21 January 2018

Identifiers

DOI

1 reference

4 November 2017

1 reference